Trial Profile
A phase I study of Cannabidiol/tetrahydrocannabinol (MedChew-1504) for the treatment of Restless Leg's Syndrome
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 22 Mar 2018
Price :
$35
*
At a glance
- Drugs Nabiximols (Primary)
- Indications Restless legs syndrome
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- 19 Mar 2018 According to an Axim Biotechnologies media release, the Company plans to complete this trial in the next 12-18 months.
- 11 Nov 2016 The profile has been written from Axim Biotech product pipeline. (http://aximbiotech.com/product-timeline/)
- 11 Nov 2016 New trial record